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CLINICAL STUDY 
Abstract  
Objective 
Describe our experience with combination therapy of Deferiprone (DFP) and 
Desferrioxamine (DFO) in treating β-Thalassemia Major patients with severe iron overload in 
Al Madinah Al Munawarah, Saudi Arabia and to determine any adverse events of  treatment.   
Methods 
Twenty eight patients with β-Thalassemia major between the ages of 8 - 27 (mean 15.5 + 4.6 
years SD) were enrolled into a prospective open label one year study from January 1st 2006 to 
December 31st 2006, at Al Madinah Maternity & Children's Hospital (Al Madinah Hereditary 
Blood Diseases Center). Participants were followed regularly at Al Madinah Hereditary 
Blood Diseases Center for at least 6 years prior to their enrolment in the study. The inclusion 
criteria were all patients who are transfusion dependent Thalassemia Major with an age of 
more than 8 years and serum ferretin levels > 3000 ng/L which were progressively increasing 
despite receiving chelating therapy with subcutaneous Desferrioxamine for at least 5 years 
prior to study. The doses used for Deferiprone was 75mg/kg while the dose of 
Desferrioxamine was 40- 50mg/kg/day. Serum ferretin and other laboratory investigations 
were monitored every 3 weeks and adverse events of both drugs were assessed regularly 
along with patients’ compliance.  
Results 
There was no significant reduction of serum ferretin from baseline and by the end of the 
study period and no serious adverse events were observed.  
Conclusion  
Deferiprone is a safe drug, however it did not reduce the serum ferretin from the base line, 
but it maintained the iron balance despite chronic transfusion in patients with β-Thalassemia 
major when used in combination with Desferrioxamine.  
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Introduction 
 
- Thalassemia is a hereditary blood 
disease characterized by the absence or 
reduction in the synthesis of β-globins 
chains of the normal hemoglobin resulting 
in an imbalance between  -and β chain and 
consequent ineffective erythropoeisis and 
hemolysis1, 2. The historical name of Cooley 
Anemia is the homozygous form of this 
disease. β- Thalassemia is endemic in all 
Arab countries and particularly among the 
Mediterranean population. 
The molecular basis of β- Thalassemia in 
various Arab Countries reveals the presence 
of 52 mutations3, which are mostly of 
Mediterranean and Asian origin. In Saudi 
Arabia 14 mutation were Identified and the 
commonest of which is IVS-1-110 (G—A), 
codon 39 (C-T) and IVS 11-1 (G—A)4-7. 
This study was conducted in Al Madinah 
and the estimated gene frequency of β-
Thalassemia turned out to be 0.1 %8. 
Al Madinah Hereditary Blood Diseases 
Center was established in 1992 at Al 
Madinah Maternity and Children Hospital. 
It serves Thalassemia patients including 
adults in Al Madinah Region. The center 
provides comprehensive management that 
includes regular blood transfusion at 2-4 
weeks intervals with regular use of 
Desferrioxamine (DFO).   
The total of currently followed Thalassemia 
patients being at the center is 80.  The 
research team first published a report on 
Thalassemia from Al Madinah region in 
20039. 
Since 1980s Desferrioxamine was the only 
Iron chelator used as subcutaneous infusion. 
The major disadvantage to this mode of 
therapy is its route of administration. 
Desferrioxamine is given subcutaneously 
with a special pump for 8-12 hrs everyday 
for at least 5 days a week placing  
considerable burden on the social and 
psychological life of the patients and their 
families. 
Deferiprone (DFP) was the first oral Iron 
chelator to be licensed for use in India in 
1995 and was granted in European license in 
2000 under special conditions. It achieved 
full license in Europe in 2002, and was 
approved as a second line drug for patients 
who are unable to use DFO or on whom 
DFO therapy had proven ineffective. 
Some studies10-12 have shown the 
effectiveness of DFP alone as an oral 
chelator but a combination therapy with 
DFO and DEP has shown to be more 
effective in reducing serum ferritin13-15 . 
Deferiprone was introduced to the Ministry 
of Health in Saudi Arabia in 2005 and has 
been used in  the Thalassemia center since 
then. Many centers however had concerns 
about its safety; hence its use was not 
universally taken up in Saudi Arabia.  
The aim of this study was to describe the 
experience with DFP in combination with 
DFO in the treatment of iron overload in β-
Thalassemia patients, and to determine its 
safety.   
 
Material and Methods 
 
This is a prospective open label 1 year study 
of combined therapy with Deferiprone and 
Desferrioxamine in β thalassemic patients 
with iron overload. 
Twenty eight patients with β-Thalassemia 
major were enrolled into the study over one 
year from January 1st 2006 to December 31st 
2006, at  Al Madinah Maternity & Children's 
Hospital (Al Madinah Hereditary Blood 
Diseases Center). The age ranges were 8-27 
years with mean ±SD, (15 ± 4. 60) all patients 
were followed regularly at the Thalassemia 
center for at least 6 years. 
Diagnosis of β-Thalassemia major was based 
on the clinical history of pallor, jaundice and 
hepatosplenomegaly with hemoglobin 
electrophoresis showing high HbF values 
(95-98%), raised HbA2 (3.5-5%) on cellulose 
acetate medium at alkaline PH 8.4 (Helena 
laboratories, 1530 Lindbergh Drive, 
Beaumont Texas,  USA). 
All patients were on chronic blood 
transfusion regimen receiving 10-15 ml/kg 
of packed red blood cells every 2-4 weeks. 
They had been receiving DFO (Desferal, 
Novartis Inc, Basel, Switzerland) at a daily 
dose of 40 – 50 mg/kg / day by 
subcutaneous infusion pump over 8-12 h for
β 
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5 nights per week for at least 5 years prior to 
the study .  
Additional intravenous DFO (50 mg/kg 
body weight), was given each time at the 
time of blood transfusion. Desferrioxamine 
were started for all patients when serum 
ferretin level reached 1000 ng/ml. 
Deferiprone was added to patients with 
severe iron overload with serum 
ferretin>3000ng/L 
All patients were screened for hepatitis C 
virus (HCV) antibody and hepatitis B 
surface antigen (Hbs Ag) with appropriate 
standard commercial assay. During the 
study period no change was allowed in the 
dose of DFP while the DFO dose was 
adjusted according to the ferretin level. 
Informed consent was obtained from all 
patients and/or their parents according to 
their age after getting the approval of the 
hospital research ethics board.    
 Inclusion Criteria:  
1- Transfusion- dependent Thalassemia  
2- Age >  8 year 
3- Serum ferritin level > 3,000 ng/L and 
progressively increasing undergoing 
chelating  therapy with subcutaneous  
DFO for more than 5 years 
 Exclusion Criteria: 
1- Severe liver, kidney or cardiac disease. 
2- Serious   adverse events with DFO or 
DFP. 
3- Neutriphil  count < 2000/L during the 
past 2 years or Platelet count < 
100,000/L 
4- History of arthropathy 
The Deferiprone (Ferriprox) (1, 2 dimethyl -
3- hydroxypyridin -4 one) (L1) provided by 
Apotex Inc, (Canada) with a dose of 
75/kg/day was administered three times 
per day and the dose was rounded down to 
the nearest tablet (500mg). DFO was 
administered at same dose 40mg/kg /day 
subcutaneously twice weekly with 
additional intravenous dose 50mg/kg 
during blood transfusion.  
Patient were assessed for adverse events of 
DFP every 3 weeks and Patients were 
advised to temporary discontinue  DFP 
during any febrile  illness  and to report to 
the hospital for evaluation of 
agranulocytosis  or neutropenia. 
All patients were assessed clinically and by 
haematological tests (Full blood count 
(hemoglobin, hematocrit, WBC count, 
absolute neutrophil count and platelet 
count) was performed at each 3 weekly visit. 
Serum ferretin level, liver and renal 
functions tests were measured at the 
beginning of the study and then every 3 
months till the completion of the study). 
If patients developed neutropenia (defined 
as neutrophil count < 1000 μl) or 
thrombocytopenia (platelet count < 100.000 
μl) DFP was temporary interrupted. If 
patients developed agranulocytosis 
(neutrophil count < 500 μl), the patients 
were excluded from the study. Joints pain if 
severe was also another cause for temporary 
interruption of DFP.  
Student's paired t-test and analysis of 
variance were used to test differences of 
mean values and the P-values were 
considered statistically significant if it was < 
0.05.  
 
Results 
 
Thirty patients were enrolled in the study, 
from which two were excluded because of 
development of severe gastrointestinal 
adverse effect with Deferiprone. Twenty 
eight patients successfully completed the 
study after 1 year: 17 males (60.7%) and 11  
females  (39.3%), the majority (68%) were 
Saudi.  
Sixteen patients (57%) were positive for 
HCV antibody, and one (3.5%) was positive 
for Hbs Ag.  
Fifteen patients (53.5%) developed mild 
nausea and abdominal pain with DFP, and 
10 patients (35.7%) developed only mild 
vomiting, while skin rashes were observed 
in two patients (7%). One patient (3.5%) 
developed arthropathy and fortunately none 
of the patients developed neutropenia, 
agranulocytosis or hepatic toxicity and the 
drug was not interrupted in any of them. 
The patients’ demographic data, selected 
clinical parameters and drug adverse events  
are outlined in Table 1. The mean pre-
transfusion Hemoglobin level was 7.8± 0.95 
mg/dl, mean serum ferritin level at baseline
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was 4450.5ng/L and at 12 months was 
4212.9 ng/L (P= 0.984), Figure 1. The mean  
 
biochemical data are given in Table 2. 
 
 
Table 1: Patients clinical data and adverse events. 
Parameters Number Percentage (%) 
Gender 
Male 
Female 
 
17 
11 
 
60.71 
39.24 
Nationality 
Saudi 
Non Saudi  
19 
9 
67.86 
32.14% 
Consanguinity  20 71.43 
Good compliance with DFO   
Good Compliance with DFP  
18 
15 
64.39 
53.57 
HIV Infection  
HBV 
HCV 
0 
1 
16 
0.00 
3.57 
57.14 
DFO Adverse events 
-local pain  
-Allergy 
Others 
 
18 
16 
0 
 
62.29 
57.14 
0 
DFP Adverse events 
Nausea  
Vomiting  
Abdominal pain  
Skin rashes 
Arthropathy 
Neutropenia  
Agranulocytosis 
Hepatic toxicity  
 
15 
10 
15 
2 
1 
0 
0 
0 
 
 
53.57 
35.71 
53.57 
7.14 
3.57 
0 
0 
0 
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 Fig 1: The mean serum ferretin at baseline and at 12 months after treatment.  
 
Table 2:  The mean biochemical data at baseline and on combination (DFO+DFP) 
Items Baseline on (DFO) 
N=28 
Combination (DFO & DFP) 
N = 28 
P. Value 
Glucose 5.344 mmo/L 5.46 mmo/L 0.624 
Sodium (Na) 139.5 mmo/L 138.6 mmo/L 0.414 
Potassium (K) 4.15 mmo/L 4.06  mmo/L 0.416 
Urea  4.12 mmo/L 5.74 mmo/L 0.366 
Creatinine 37.41 μmo/L 45. 37 μmo/L 0.008 * 
AST 94.21 u/L 93.8 u/L 0.970 
ALT 86.84 u/L 97.50 u/L 0.316 
ALP 231. 54 u/L 191.67 u/L 0.0009 * 
T. Billirubin   50.86 μmo/L 43.90 μmo/L 0.110 
 
Group 1 Group 2 
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Discussion 
 
This is the first published study highlighting 
the local experience with Deferiprone in the 
treatment of patients with β-Thalassemia 
major with high serum ferretin receiving 
standard iron chelating agent 
Desferrioxamine in Saudi Arabia. 
The efficacy of the chronic use of DFO in 
preventing iron- induced organ damage and 
reducing morbidity and mortality in 
transfusion-dependent patients is well 
documented16, 17. However the main 
limitation of its use and parenteral 
administration using prolonged 
subcutaneous infusion, which frequently 
results in poor compliance by patients 
especially adolescents.  Deferiprone an oral 
agent has recently been approved for 
treatment of iron overload in transfusion 
dependent patients18. Furthermore when 
combined with DFO   significant 
improvement in efficacy of iron chelation 
has been reported15, 19, 20. It is hoped that this 
approach will improve patient’s compliance 
to iron chelation.  
Our study shows no significant difference 
on serum ferretin level at 1 year after 
switching transfusion dependent β-
Thalassemia patients with high serum 
ferretin on DFO alone to combination of 
DFP and DFO (P value of 0.984), which is 
consistent with other studies21, 22. 
Therefore, combination therapy had an 
advantage in keeping a balanced iron load 
in those patients with inadequate  responses 
to DFO monotherapy, it is as effective as 
using DFO 5 days per week, in many recent 
studies of combination therapy that have 
demonstrated significant decrease in serum 
ferretin compare to DFO monotherapy23-26, 
which was demonstrated in some of the 
patients in this study.  
Results consistent with the findings of the 
Cochrane systemic review 2007 which 
reported no consistent effect on the 
reduction of iron overload between   
treatment with  Deferiprone and DFO with 
exception of urinary excretion. The authors 
recommended using Deferiprone in treating 
iron overload in patients with β- 
Thalassemia major when Desferrioxamine is 
either contraindicated or inadequate27.  
DFP showed a significant improvement in 
the myocardial performance as reported in 
many studies21, 28, 29. 
It has been documented during the last 
several years that the accurate assessment of 
myocardial iron should be evaluated using 
the T2* Magnetic Resonance (MR) technique 
in B-Thalassemia as myocardial iron does 
not correlate with serum iron.   
It is recommended to use MRI for assessing 
myocardial iron in routine clinical 
management of patients with β-Thalassemia 
major [30].Cardiac evaluation was not done 
in this study as T2* MRI is not available in 
Al Madinah, nor; was echocardiography 
used for the assessment of myocardial 
performance. 
None of the patients in the study developed 
serious adverse events, namely 
agranulocytosis or neutropenia which 
necessitate withdrawal from the study 
(Table 1) as observed in recent reports22. 
The major adverse events in the study were 
gastrointestinal symptoms (Nausea, 
vomiting and abdominal pain), which were 
consistent with other studies31, 32. 
Only one patient (3.5%) developed mild 
arthropathy which resolved spontaneously 
with time. 32% of the patients in the study 
were non-splenectomized and none of them 
developed neutropenia, which contradicts 
others findings of significant association of 
neutropenia in non splenectomized 
patients31. 
There were no significant changes in ALT 
from baseline and after combination therapy 
observed (P value 0.316), but there were 
significant increases in serum creatinine 
levels when combination therapy was used 
(P value 0.008) but none of the patients 
developed renal or heart failure and this 
contrasts with other reports where serum 
creatinine remained normal33. 
The study demonstrates a significant 
reduction of serum Alkaline Phosphatase 
from the baseline (Table 3; P value 0.008) 
with no clear explainations. Hence, further 
studies are required to confirm or refute this 
finding.  
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The study also agrees with the Italian 
Society of Hematology Practice Guidelines 
for management of iron overload in 
Thalassemia major34 where the expert panel 
recommend that patients, who developed 
severe iron overload (serum ferretin>3000 
ng/ml.) on DFO should receive combined 
Iron chelating therapy and the first choice 
for combined therapy is DFO with DFP or to 
receive intensive Desferrioxamine therapy.   
Deferasirox (Exjade, Novartis) is a new oral 
iron chelator, it is orally bio-available and its 
half-life is between 8 and 16 hours, allowing 
administration once a day. It is the first FDA 
oral iron chelator approved in the USA in 
November 2005.  Phase 3 trials 
demonstrated similar efficacy to 
Desferrioxamine35, and the data revealed 
that chelation efficiency of Deferasirox was 
twice that of DFO36. Data on cardiac iron 
chelation is limited although some studies 
have shown it is comparable to 
Deferiprone37, 38. 
Finally, the study agrees with the recent 
recommendations39 that the safety and 
efficacy records of DFP, DFO and their 
combination in particular appears to 
provide a universal solution in the treatment 
of severe iron overload and transfusion 
dependent Thalassemia major, as well as in 
reducing mortality because of their ability to 
clear rapidly and effectively excess cardiac 
Iron. However Deferasirox is to be 
considered as the first line oral chelator.  
 
Conclusion  
 
Deferiprone is a safe drug, however does 
not reduce the serum ferretin from the 
baseline, but it maintains the iron balance 
despite chronic blood transfusion in patients 
with β-Thalassemia major when used in 
combination with Desferrioxamine.  
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